Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, multicenter, randomized clinical study of efficacy, safety, and optimal dosage selection of VM-1500 versus Efavirenz within the background of standard basic antiretroviral therapy, consisting of two nucleoside/nucleotide reverse transcriptase inhibitors, in HIV-1 infected treatment-naïve patients

Trial Profile

An International, multicenter, randomized clinical study of efficacy, safety, and optimal dosage selection of VM-1500 versus Efavirenz within the background of standard basic antiretroviral therapy, consisting of two nucleoside/nucleotide reverse transcriptase inhibitors, in HIV-1 infected treatment-naïve patients

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2018

At a glance

  • Drugs Elsulfavirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2018 96-Week results presented at the 22nd International AIDS Conference
    • 19 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top